Leadership

Led by passionate people who have walked in your shoes.

Genesis is run by healthcare leaders who understand the challenges of high-volume supply chain management, as well as the requirements of the clinical setting. We know the view from your side of the table, and we’re committed to providing you with a different kind of technology experience—one marked by requirements addressed, promises met, and value delivered.

Meet the Genesis Board of Directors

Geoffrey Hamilton Fairley

Geoffrey Hamilton-Fairley

Non-Executive Director

LinkedIn

Geoffrey Hamilton-Fairley is an experienced Chairman, NED and investment advisor with a track record of leading companies at different stages of development from start-ups through to sale and IPO. 

His entrepreneurial career started in 1982, founding a number of companies in Public Relations, Technology, Advertising and Music & Personality management backed by The Abingdon Management Company Limited, where he subsequently became sole owner having acquired Abingdon from its institutional shareholders. Abingdon had a number of quoted and unquoted investments including a Unit Trust, Foretronic (a technology company that introduced the magnetic data strip on the back of credit cards),  TVS (ITV franchise for the South of England), and a significant property portfolio in the UK and abroad. 

Returning to his medical roots, Geoffrey developed and guided Oncimmune, a company pioneering technologies to enable early cancer detection, from a Nottingham University start-up through to a successful IPO in May 2016, with total funds raised of £62m. During this period he co-authored numerous scientific and health economic publications. 

He now acts as an advisor to leading technology and healthcare funds, advising investment teams, specific due diligence projects, monitoring investments as a director and mentoring CEOs. 

Geoffrey Hamilton Fairley

Geoffrey Hamilton-Fairley

Non-Executive Director

 

Scott Bagwell

Scott Bagwell

Non-Executive Chairman

LinkedIn

Scott has more than 25 years of industry experience leading sales and marketing teams for leading health care technology companies. He currently sits on the Board of Directors with Verisys and also on the Board of EnableComp, and is a former President of Experian Health. Prior to this, Bagwell served as Senior Vice President of Sales & Marketing and Professional Services at Experian Health and at Passport Health Communications. Before joining Passport Health in 2010, he served as Senior Vice President for McKesson Pharmacy Systems and RelayHealth Pharmacy business units. He also held senior executive positions at Per-Se Technologies / NDCHealth Corporation, as well as Sunquest Information Systems / Misys.

Scott Bagwell

Scott Bagwell

Non-Executive Chairman

 

Noel Ohanlon

Noel O’Hanlon

CEO

LinkedIn

Noel has 25 years of senior management experience as Director and Managing Director in high-tech manufacturing and software technology-based companies. He founded Genesis in 2010 to bring innovative supply chain technology solutions and best practice processes—proven in other sectors—to healthcare, with an aim to improve the quality and efficiency of patient care. Since then, Genesis has grown to become the Point of Care Traceability and Inventory Management solutions market leader in the UK. In 2017, Noel expanded the company and solution offerings to the United States, with a head office located in St. Petersburg, FL. The company is flourishing, with a 100% annual growth rate.

Noel Ohanlon

Noel O’Hanlon

CEO

 

Ian Mcdermott

Ian McDermott

CFO

LinkedIn

Ian is responsible for all aspects of financial and commercial governance across the group. He is a member of The Institute of Chartered Accountants Ireland and has experience across a wide variety of industries, including information technology, building materials, construction, medical technology, bio sciences, manufacturing, pharmaceutical, software solutions and professional services. Prior to Genesis, Ian worked on the corporate development team of an FTSE 100 company as well as with Deloitte across both assurance and corporate finance practices.

Ian Mcdermott

Ian McDermott

CFO

 

Edward Denor

Edward De Nor

Non-Executive Director

LinkedIn

Edward is an experienced private equity executive with 25 years of financial and principal investing experience. He has spent the last ten years focused on growth investments in the European mid-market. Prior to that, he was Regional Head of the UK and Northern European private equity business for Goldman Sachs’ Principal Investments Area, where he was responsible for over $1bn of investment in five portfolio companies in Europe and North America. Edward began his career with IBM in engineering and corporate development, working then with technologies that are prevalent in the healthcare industry today.

Edward Denor

Edward De Nor

Non-Executive Director

 

Jack Daly

Jack Daly

Non-Executive Director

LinkedIn

Jack is the Managing Director at IPP Ltd (Ireland) and Anglo Production Processes Ltd (UK). Jack’s background is in electronics manufacturing, where he worked for many years as a senior engineer. Jack then joined IPT in 1998; since then he applied his process and lean manufacturing knowledge to the business to become the leading distributors of equipment in the UK and Ireland. In 2012 Jack took over as MD at IPP and APP and established the Life Sciences business unit within these companies focusing on product and pack inspection / serialization. This business unit combined with the traditional electronics manufacturing equipment has proven to be a very successful business model.

Jack Daly

Jack Daly

Non-Executive Director

 

Raeto Guler

Raeto Guler

Board Observor

LinkedIn

Raeto has 10 years of experience in specialized debt financing and investing. He was previously at Macquarie in the Special Situations Lending team and at Barclays Capital in Leveraged Finance. He has significant transaction experience across a range of sectors and jurisdictions. He hold an MA in Banking and Finance from HSG, Switzerland, and SSE, Sweden.

Raeto Guler

Raeto Guler

Board Observor

 

Tmb Cornel Riklin

Cornel Riklin

Non-Executive Director

LinkedIn

Cornel Riklin, Non-Executive Director, has over 20 years’ experience both as a company CEO and Managing Director and as a private equity investor. He is a founding partner of Caphaven LLP a private equity firm focussing on small company buy-outs and growth investments. Previously Cornel was CEO of two private equity owned businesses, European Directories and Findexa, and a partner at TPG Capital. Prior positions include Group Managing Director at Trinity Mirror plc, CEO of Borthwicks plc and five years as a strategy consultant at Bain & Company.  

Over the years Cornel has served on the board of a series of public and private companies and he holds an MBA from Harvard Business School. 

Tmb Cornel Riklin

Cornel Riklin

Non-Executive Director

 

Meet the Genesis Leadership

Noel Ohanlon

Noel O’Hanlon

CEO

LinkedIn

Noel has 25 years of senior management experience as Director and Managing Director in high-tech manufacturing and software technology-based companies. He founded Genesis in 2010 to bring innovative supply chain technology solutions and best practice processes—proven in other sectors—to healthcare, with an aim to improve the quality and efficiency of patient care. Since then, Genesis has grown to become the Point of Care Traceability and Inventory Management solutions market leader in the UK. In 2017, Noel expanded the company and solution offerings to the United States, with a head office located in St. Petersburg, FL. The company is flourishing, with a 100% annual growth rate.

Noel Ohanlon

Noel O’Hanlon

CEO

 

Mike Oflynn

Mike O’Flynn

CTO

LinkedIn

Mike has over 10 years of technology leadership and senior management experience in software-based companies. He is responsible for all aspects of product, technology and data analytics across the Genesis group. Having joined Genesis in 2012, Mike has collaborated closely with healthcare leaders to develop innovative technology solutions across the clinical supply chain, which has led to Genesis being the market leader in the UK. Mike has been responsible for establishing and expanding the R&D group, the professional services organization in the UK, and supporting commercial operations in the US.

Mike Oflynn

Mike O’Flynn

CTO

 

Ian Mcdermott

Ian McDermott

CFO

LinkedIn

Ian is responsible for all aspects of financial and commercial governance across the group. He is a member of The Institute of Chartered Accountants Ireland and has experience across a wide variety of industries, including information technology, building materials, construction, medical technology, bio sciences, manufacturing, pharmaceutical, software solutions and professional services. Prior to Genesis, Ian worked on the corporate development team of an FTSE 100 company as well as with Deloitte across both assurance and corporate finance practices.

Ian Mcdermott

Ian McDermott

CFO

 

Mark Hendricks

Mark Hendricks

COO

LinkedIn

Mark is a healthcare information technology professional with over 25 years of operational, technical, consultative sales, and sales management experience for care providers, information technology solution providers, and healthcare consultancies. He has demonstrated success and proven results to solve healthcare operational challenges and business issues by designing, selling, and delivering solutions that include the appropriate mix of technology, applications, operational redesign, and change management.

Mark Hendricks

Mark Hendricks

COO

 

Insights on Clinical Traceability.

Clinical Traceability Solution
Featured Resource

The Clinical Traceability Solution
Buyer’s Guide

With clinical traceability, hospital systems can finally manage their care-critical supplies in a data-driven way. Use this insightful buyer’s guide to learn why clinical traceability is the future and guide your hospital’s search for the right solution.

Download Now

Seeing is Believing

Request a free demo and discover firsthand how Genesis delivers real value through complete clinical traceability.